Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses

Emerg Microbes Infect. 2021 Dec;10(1):905-912. doi: 10.1080/22221751.2021.1919032.

Abstract

Without an effective vaccine against SARS-CoV-2, the build-up of herd immunity through natural infection has been suggested as a means to control COVID-19. Although population immunity is typically estimated by the serological investigation of recovered patients, humoral immunity in asymptomatic subjects has not been well studied, although they represent a large proportion of all SARS-CoV-2 infection cases. In this study, we conducted a serosurvey of asymptomatic infections among food workers and performed serological and cellular response analyses of asymptomatic subjects in Wuhan, the original epicenter of the COVID-19 outbreak. Our data showed that up to 5.91% of the food workers carried SARS-CoV-2 IgG antibodies asymptomatically; however, in 90.4% of them, the antibody level declined over a 2-week period. IgM and IgG antibodies, including neutralizing antibodies, were significantly lower in asymptomatic subjects than in recovered symptomatic patients with similar disease courses. Furthermore, the asymptomatic subjects showed lymphopenia and a prominent decrease in the B-cell population, as well as a low frequency of antibody-secreting cells and a low cytokine response. These factors probably contributed to the low and unsustained antibody levels in asymptomatic subjects. Our results show that asymptomatic subjects are likely to be vulnerable to SARS-CoV-2 reinfection, and neither the proportion of population immunity nor the breadth of immune responses is sufficient for herd immunity.

Keywords: COVID-19; SARS-CoV-2; asymptomatic; serology; weak antibody response.

MeSH terms

  • Antibodies, Neutralizing / biosynthesis
  • Antibodies, Neutralizing / blood*
  • Antibodies, Viral / biosynthesis
  • Antibodies, Viral / blood*
  • Asymptomatic Infections*
  • B-Lymphocytes
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • COVID-19 Nucleic Acid Testing
  • COVID-19 Serological Testing*
  • China / epidemiology
  • Convalescence
  • Cytokines / blood
  • Disease Susceptibility
  • Enzyme-Linked Immunosorbent Assay
  • Follow-Up Studies
  • Food Handling
  • Genome, Viral
  • Humans
  • Immunity, Herd
  • Immunoglobulin G / biosynthesis
  • Immunoglobulin G / blood*
  • Immunoglobulin M / biosynthesis
  • Immunoglobulin M / blood*
  • Lymphocyte Count
  • Lymphopenia / etiology
  • Pandemics*
  • Phylogeny
  • RNA, Viral / blood
  • Real-Time Polymerase Chain Reaction
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology*
  • Seroepidemiologic Studies
  • Sputum / virology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Cytokines
  • Immunoglobulin G
  • Immunoglobulin M
  • RNA, Viral

Grants and funding

This work was funded by Ministry of Science and Technology of China (grant numbers 2020YFC0861100 and 2020YFC0840900 to PZ), the Natural Science Foundation of China (excellent scholars grant numbers 81822028 and 82041013 to PZ) and The Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29050100 to XEZ).